^
Association details:
| Biomarker: | STRN-ALK fusion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
Excerpt:
Here, we report the first case of STRN-ALK fusion–positive BC in a patient who responded to alectinib….Based on the presence of the STRN-ALK fusion, the patient was started on alectinib with a baseline CT shown at day 7 of treatment...There appeared to be continued response in bone lesions and lymph nodes, with increased cfDNA to 19.45 ng/mL at the time of this writing, and the patient decided not to pursue additional lines of therapy or testing.
DOI:
10.1200/PO.21.00142
